News Home

Is Legend Biotech Corp (LEGN) a Good Choice in Biotechnology Tuesday?

Tuesday, October 19, 2021 02:46 PM | InvestorsObserver Analysts
Is Legend Biotech Corp (LEGN) a Good Choice in Biotechnology Tuesday?

Legend Biotech Corp (LEGN) is around the top of the Biotechnology industry according to InvestorsObserver. LEGN received an overall rating of 58, which means that it scores higher than 58 percent of all stocks. Legend Biotech Corp also achieved a score of 86 in the Biotechnology industry, putting it above 86 percent of Biotechnology stocks. Biotechnology is ranked 87 out of the 148 industries.

Overall Score - 58
LEGN has an Overall Score of 58. Find out what this means to you and get the rest of the rankings on LEGN!

What do These Ratings Mean?

Finding the best stocks can be tricky. It isn’t easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObserver’s tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector. This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

What's Happening With Legend Biotech Corp Stock Today?

Legend Biotech Corp (LEGN) stock is trading at $54.54 as of 2:36 PM on Tuesday, Oct 19, a rise of $3.03, or 5.88% from the previous closing price of $51.51. The stock has traded between $51.81 and $55.81 so far today. Volume today is less active than usual. So far 285,681 shares have traded compared to average volume of 472,553 shares. Click Here to get the full Stock Report for Legend Biotech Corp stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App